Physician profile
Paramveer Singh
NPI 1154777308
$1,872.82
in general payments reported to CMS, 2019-2025
16 companies · $345 in 2025
The $345 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $621 · 2022: $351 · 2023: $371 · 2024: $184 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525 · Education: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.48 |
| Education | $374.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $371.99 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $276.99 | 2024-2025 | Soliris |
| Sanofi-Aventis U.S. LLC | $166.99 | 2021-2022 | |
| Epizyme, INC. | $162.94 | 2021-2022 | |
| Adaptive Biotechnologies Corporation | $145.61 | 2025 | Clonoseq |
| Amgen INC. | $125.00 | 2023 | Blincyto |
| Kite Pharma, INC. | $123.48 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.35 | 2023 | Onureg |
| Incyte Corporation | $99.95 | 2021 | |
| Abbvie INC. | $95.00 | 2021 | |
| Beigene USA, INC. | $50.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.17 | 2025 | |
| Syndax Pharmaceuticals, INC. | $28.72 | 2025 | Revuforj |
| Celgene Corporation | $25.00 | 2023 | Pomalyst |
| Genentech USA, INC. | $24.07 | 2025 | Venclexta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $21.56 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paramveer Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.